Optimized lymph node dissection range during progression of lower thoracic esophageal squamous cell carcinoma in the latest therapeutic surgical strategy: A retrospective analysis

Ozawa S, Tachimori Y, Baba H, Matsubara H, Muro K, Numasaki H, Oyama T, Shinoda M, Takeuchi H, Tanaka O, et al: Comprehesive registry of esophageal cancer in Japan, 2002. Esophagus. 7:7–22. 2010. View Article : Google Scholar

Li H, Zhang Y, Cai H and Xiang J: Pattern of lymph node metastases in patients with squamous cell carcinoma of the thoracic esophagus who underwent three-field lymphadenectomy. Eur Surg Res. 39:1–6. 2007. View Article : Google Scholar : PubMed/NCBI

Igaki H, Tachimori Y and Kato H: Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Ann Surg. 239:483–490. 2004. View Article : Google Scholar : PubMed/NCBI

Fujita H, Sueyoshi S, Tanaka T and Shirouzu K: Three-field dissection for squamous cell carcinoma in the thoracic esophagus. Ann Thorac Cardiovasc Surg. 8:328–335. 2002.PubMed/NCBI

Shimada Y, Imamura M, Sato F, Maeda M, Kaganoi J, Hashimoto Y, Kan T, Nagatani S and Li Z: Indications for abdominal para-aortic lymph node dissection in patients with esophageal squamous cell carcinoma. Surgery. 132:93–99. 2002. View Article : Google Scholar : PubMed/NCBI

Ye K, Xu JH, Sun YF, Lin JA and Zheng ZG: Characteristics and clinical significance of lymph node metastases near the recurrent laryngeal nerve from thoracic esophageal carcinoma. Genet Mol Res. 13:6411–6419. 2014. View Article : Google Scholar : PubMed/NCBI

Katada N, Yamashita K, Katada C, Moriya H, Hosoda K, Mieno H, Higuchi K, Komori S, Ishiyama H, Hayakawa K, et al: Neoadjuvant chemotherapy using concurrent Docetaxel/CDDP/5-FU (DCF) in esophageal squamous cell carcinoma and its short-term prognosis. Esophagus. 11:173–181. 2014. View Article : Google Scholar

Yamashita K, Katada N, Moriya H, Hosoda K, Mieno H, Katada C, Koizumi W, Hoshi K and Watanabe M: Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. Gen Thorac Cardiovasc Surg. 64:209–215. 2016. View Article : Google Scholar : PubMed/NCBI

Japanese Society for Esophageal Disease: Guideline for the clinical and pathological studies on carcinoma of the esophagus. 10th edition. revised. Kanehara & Co., Ltd; Tokyo: 2002

Nishimaki T, Suzuki T, Tanaka Y, Nakagawa S, Aizawa K and Hatakeyama K: Evaluating the rational extent of dissection in radical esophagectomy for invasive carcinoma of the thoracic esophagus. Surg Today. 27:3–8. 1997. View Article : Google Scholar : PubMed/NCBI

Motoyama S, Kitamura M, Saito R, Maruyama K, Okuyama M and Ogawa J: Outcome and treatment strategy for mid- and lower-thoracic esophageal cancer recurring locally in the lymph nodes of the neck. World J Surg. 30:191–198. 2006. View Article : Google Scholar : PubMed/NCBI

Yamashita K, Hosoda K, Moriya H, Katada C, Sugawara M, Mieno H, Komori S, Katada N and Watanabe M: Prognostic advantage of docetaxel/cisplatin/ 5-fluorouracil neoadjuvant chemotherapy in clinical stage II/III esophageal squamous cell carcinoma due to excellent control of preoperative disease and postoperative lymph node recurrence. Oncology. 92:221–228. 2017. View Article : Google Scholar : PubMed/NCBI

Tachimori Y, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, Oyama T, Toh Y, Udagawa H and Uno T: Registration Committee for Esophageal Cancer of the Japan Esophageal Society: Comprehensive registry of esophageal cancer in Japan, 2010. Esophagus. 14:189–214. 2017. View Article : Google Scholar : PubMed/NCBI

Yang HX, Hou X, Liu QW, Zhang LJ, Liu JG, Lin P and Fu JH: Tumor location does not impact long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China. Ann Thorac Surg. 93:1861–1866. 2012. View Article : Google Scholar : PubMed/NCBI